Price Action to Note: SCYNEXIS Inc Declines A lot Today, Is Now One of The Worst Performer

Price Action to Note: SCYNEXIS Inc Declines A lot Today, Is Now One of The Worst Performer

The stock of SCYNEXIS Inc (NASDAQ:SCYX) is a huge mover today! About 592,251 shares traded hands. SCYNEXIS Inc (NASDAQ:SCYX) has risen 13.76% since March 7, 2016 and is uptrending. It has outperformed by 6.17% the S&P500.
The move comes after 8 months negative chart setup for the $117.63 million company. It was reported on Oct, 10 by Barchart.com. We have $4.39 PT which if reached, will make NASDAQ:SCYX worth $11.76M less.

Analysts await SCYNEXIS Inc (NASDAQ:SCYX) to report earnings on November, 11.

SCYNEXIS Inc (NASDAQ:SCYX) Ratings Coverage

Out of 5 analysts covering Scynexis Inc (NASDAQ:SCYX), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Scynexis Inc has been the topic of 8 analyst reports since August 20, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by Brean Capital on Monday, March 28. The stock of SCYNEXIS Inc (NASDAQ:SCYX) has “Strong Buy” rating given on Friday, October 7 by WBB Securities. The company was initiated on Tuesday, December 29 by WBB Securities. The rating was maintained by RBC Capital Markets on Monday, November 16 with “Outperform”. On Wednesday, August 17 the stock rating was initiated by Guggenheim with “Buy”. WBB Securities upgraded SCYNEXIS Inc (NASDAQ:SCYX) on Tuesday, August 9 to “Buy” rating. The firm has “Buy” rating by Brean Capital given on Monday, October 3. As per Thursday, August 20, the company rating was maintained by Needham.

According to Zacks Investment Research, “SCYNEXIS, Inc. is a pharmaceutical company. It is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. It also provides contract research and development services. SCYNEXIS, Inc. is headquartered in Durham, North Carolina.”

Insitutional Activity: The institutional sentiment increased to 1.82 in 2016 Q2. Its up 0.02, from 1.8 in 2016Q1. The ratio is positive, as 4 funds sold all SCYNEXIS Inc shares owned while 7 reduced positions. 10 funds bought stakes while 10 increased positions. They now own 13.69 million shares or 61.88% more from 8.46 million shares in 2016Q1.
Blackrock Fund accumulated 0% or 30,090 shares. The Illinois-based Ubs Oconnor Ltd Llc has invested 0% in SCYNEXIS Inc (NASDAQ:SCYX). Highland Cap L P last reported 566,667 shares in the company. National Bank & Trust Of America De owns 5,267 shares or 0% of their US portfolio. Dafna Ltd Liability has 0.46% invested in the company for 266,904 shares. Kcg Holding holds 0% or 11,319 shares in its portfolio. Principal Fin Gp Inc reported 202,938 shares or 0% of all its holdings. Broadfin Limited Liability, a New York-based fund reported 1.48 million shares. Sabby Mngmt Limited Liability Company owns 572,928 shares or 0.06% of their US portfolio. The Germany-based Deutsche Bancorp Ag has invested 0% in SCYNEXIS Inc (NASDAQ:SCYX). Armistice Ltd holds 0.58% of its portfolio in SCYNEXIS Inc (NASDAQ:SCYX) for 698,000 shares. Geode Mngmt Limited Liability Company has 55,168 shares for 0% of their US portfolio. Nomura Hldg Inc has 14,000 shares for 0% of their US portfolio. California Employees Retirement holds 200,000 shares or 0% of its portfolio. Ladenburg Thalmann Financial holds 0% of its portfolio in SCYNEXIS Inc (NASDAQ:SCYX) for 3,156 shares.

Insider Transactions: Since May 19, 2016, the stock had 7 insider buys, and 0 sales for $276,683 net activity. Machado Patrick had bought 40,000 shares worth $117,600. Angulo Gonzalez David bought $82,159 worth of stock or 36,950 shares. Shares for $787 were bought by Taglietti Marco. HANHAM ANN bought 4,225 shares worth $15,379.

More news for SCYNEXIS Inc (NASDAQ:SCYX) were recently published by: Globenewswire.com, which released: “SCYNEXIS, Inc. to Present at the Ladenburg Thalmann Healthcare Conference” on September 20, 2016. Globenewswire.com‘s article titled: “SCYNEXIS, Inc. Receives Orphan Drug Designation for SCY-078 for the Treatment …” and published on August 24, 2016 is yet another important article.

SCYX Company Profile

SCYNEXIS, Inc., incorporated on November 4, 1999, is a pharmaceutical company, which is engaged in the discovery, development and commercialization of anti-infectives to address unmet therapeutic needs. The Firm is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. It also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. Candida and Aspergillus species are the fungi responsible for all invasive fungal infections in the United States and Europe. The Firm has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment